AVANIR Pharmaceuticals NASDAQ:AVNR recently declared the appointment of William (Bill) Sibold to the position of senior vice president and chief commercial officer. In his new role Sibold will be responsible for leading all of the company’s commercial activities.
Sibold possesses over 20 years of experience in the biopharmaceutical industry and has worked on significant products including Prozac, Avonex and Tysabri. As his most recent commercial leadership role he served as senior vice president, US Commercial for Biogen Idec Inc, where he was responsible for all commercial activities, across Biogen Idec’s neurology, oncology and rheumatology US businesses.
Sibold also held several international and domestic leadership positions at Biogen Idec prior to his role as senior vice president.
AVANIR Pharmaceuticals NASDAQ:AVNR on April 12, 2011 decreased 4.81% with the closing price of $3.76. The overall volume in the last trading session was 6.18 million shares. Its fifty two week range was $1.31-$5.80. The total market capitalization remained $457.11 million.
The AVNR share price is above from its 52 week low with 187.02% and going below from its 52 week high price with 35.17%. In the current year its earnings per share experienced growth with 111.10% while its quarter performance included -15.70%. The AVNR stock price is moving behind from its 20 days moving average with 3.06% and it is going below from its 50 days moving average with 2.70%.
AVNR has its stock institutional ownership remained 65.07% while its insider ownership recorded 1.57%. In its share capital AVNR has 121.57 million shares outstanding and among them 121.22 million shares have been floated in market exchange while the last month share price volatility included 4.43%. Company’s market risk identifying beta coefficient recorded 2.45. The beta coefficient is a measure that helps in identification of market risk associated with trading.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of Company’s commitment, Avanir has extensively invested in pipeline and is dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.
